Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a clinical-stage biopharmaceutical company based in Irvine, California, dedicated to the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Founded in 2016, Tarsus stands at the forefront of eye care innovation with a mission to revolutionize treatments for patients by addressing unmet needs through proven science and new technology.
The company’s flagship product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, was approved by the FDA in 2023. XDEMVY is a pioneering eye drop designed to treat Demodex blepharitis, a common eyelid inflammation caused by an infestation of Demodex mites. Clinical trials involving more than 800 patients demonstrated its efficacy, meeting primary and secondary endpoints with no serious treatment-related adverse events.
Beyond XDEMVY, Tarsus is advancing a diverse pipeline of therapeutic candidates. TP-03 is under investigation for the treatment of Meibomian Gland Disease (MGD), a condition often comorbid with Demodex infestation. TP-04 is being developed for the treatment of papulopustular rosacea (PPR), while TP-05 is explored as a groundbreaking oral prophylactic for Lyme disease and community malaria reduction.
The company’s recent achievements underscore its commitment to advancing therapeutic options in ophthalmology and beyond. Tarsus reported significant clinical improvements in MGD with TP-03, highlighting its potential to address underlying causes of the disease. Additionally, TP-05 showed promising results in early trials, demonstrating high tick mortality rates and suggesting potential as an on-demand prophylactic against Lyme disease.
Tarsus Pharmaceuticals collaborates with leading institutions like Tufts University School of Medicine to bolster its research endeavors. The company is also gaining traction in the marketplace, evidenced by strong quarterly financial results and strategic partnerships with major investment firms such as Goldman Sachs, BofA Securities, and Guggenheim Securities.
With ongoing consumer awareness campaigns such as “Mite Party” for XDEMVY, Tarsus is actively engaging patients and healthcare providers to improve diagnosis and treatment outcomes for Demodex blepharitis. This multi-channel initiative aims to educate the public about the prevalence and impact of Demodex infestation, encouraging patients to seek professional care.
Committed to patient-centric innovation, Tarsus Pharmaceuticals continues to expand its footprint in eye care and explore new therapeutic frontiers, striving to make a significant impact on public health through scientifically driven solutions.
Tarsus Pharmaceuticals (NASDAQ: TARS) presented findings from the Atlas Continuation study, highlighting the burden of Demodex blepharitis on patients' lives at the ARVO 2022 Annual Meeting. The research showcases the need for effective treatments, as current options are inadequate. Furthermore, Tarsus plans to submit a New Drug Application for its lead treatment, TP-03, which showed positive results in pivotal trials involving 833 patients. This investigational therapy targets Demodex mites, offering hope for millions suffering from this condition.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced an upsized public offering of 5.6 million shares at $13.50 each, totaling approximately $75.6 million before discounts. The underwriters also received a 30-day option for an additional 840,000 shares. The offering is expected to close around May 5, 2022, subject to conditions. The shares will be sold by Tarsus under an effective shelf registration statement filed with the SEC. Tarsus focuses on innovative treatments in eye care and is advancing its pipeline of investigational drugs.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced a $50 million public offering of its common stock, with underwriters receiving a 30-day option for an additional 15% of shares. The offering is reliant on market conditions and other factors, with no guarantee of completion or specified terms. BofA Securities, Jefferies, Barclays, and Raymond James are managing the offering, with preliminary documentation to be submitted to the SEC. Tarsus aims to utilize the proceeds to advance its therapies, including TP-03 for eye care and TP-05 for Lyme disease prevention.
Tarsus Pharmaceuticals announced positive results from the Saturn-2 Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for treating Demodex blepharitis. The trial met its primary endpoint, with 56% of patients achieving complete collarette cure, compared to 13% on the vehicle. Secondary endpoints showed significant improvements in mite eradication and complete lid erythema cure. TP-03 also demonstrated a favorable safety profile. Tarsus plans to submit a New Drug Application to the FDA in the second half of 2022, potentially benefiting 25 million U.S. patients.
Tarsus Pharmaceuticals (NASDAQ: TARS) will host a webcast on May 2, 2022, at 5:00am PT to discuss the topline results from the Saturn-2 Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for treating Demodex blepharitis. This trial is part of Tarsus's mission to revolutionize treatment in eye care with innovative therapies. In addition to TP-03, the company is advancing other investigational medicines targeting high unmet needs in eye care and infectious disease prevention. The webcast will be available for 90 days post-event.
Tarsus Pharmaceuticals (NASDAQ: TARS) presented significant findings at the ASCRS 2022 Annual Meeting, highlighting the substantial impact of Demodex blepharitis on patients' daily lives. The Atlas Continuation study revealed ongoing challenges for patients, while the Pandora study focused on bacterial counts. CEO Bobak Azamian emphasized the urgent need for effective treatment options as the company prepares to share topline results from the pivotal Saturn-2 trial for TP-03, an investigational treatment targeting Demodex mites, which currently has no FDA-approved solutions.
Tarsus Pharmaceuticals (NASDAQ: TARS) reported substantial advancements in its pipeline, particularly for TP-03, targeting Demodex blepharitis, with pivotal Saturn-2 trial data expected in April 2022 and NDA submission planned within the year. The company completed enrollment in this trial, following successful results from the Saturn-1 trial. Tarsus holds $171.8 million in cash as of December 31, 2021, ensuring a cash runway into the second half of 2024. The firm also advanced TP-05 for Lyme disease and secured a $175 million non-dilutive credit facility, enhancing financial flexibility and growth potential.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced its participation in two major healthcare conferences on March 16, 2022. The company will engage in a virtual fireside chat at the Oppenheimer’s 32nd Annual Healthcare Conference at 9:40am PT and a corporate presentation at the Barclays Global Healthcare Conference at 1:50pm PT. Tarsus focuses on innovative treatments in eye care and other therapeutic categories, with investigational products in clinical trials addressing significant unmet needs. Live webcasts will be available on their website.
Tarsus Pharmaceuticals has appointed Dr. José Trevejo as Chief Medical Officer, bringing over 20 years of clinical development experience. This strategic move aims to advance TP-03, Tarsus' investigational treatment for Demodex blepharitis, with an NDA submission anticipated later this year. Dr. Trevejo's expertise in drug development and infectious diseases is expected to enhance Tarsus' pipeline across various therapeutic areas. The company is currently conducting its second pivotal trial for TP-03, while also developing TP-05 for Lyme disease prevention.
Tarsus Pharmaceuticals (NASDAQ: TARS) is hosting a live webcast on February 8, 2022, at 9 a.m. PT, focusing on Demodex blepharitis and its investigational treatment TP-03. Expert speakers include CEO Bobak Azamian and leading ophthalmologists Eric Donnenfeld, Paul Karpecki, and Elizabeth Yeu. The agenda includes insights into the prevalence of Demodex blepharitis, clinical data for TP-03, and a Q&A session. TP-03, an anti-parasitic solution, has shown promise in clinical trials and targets a significant unmet need in eye care.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
What is Tarsus Pharmaceuticals' main focus?
What is XDEMVY?
What are the current projects of Tarsus Pharmaceuticals?
What recent achievements has Tarsus Pharmaceuticals accomplished?
Who are the key partners of Tarsus Pharmaceuticals?
Where is Tarsus Pharmaceuticals headquartered?
What is Demodex blepharitis?
What are the side effects of XDEMVY?
What is TP-03?
How does TP-05 work?
